Sempra DEF 14A proxy statements

Sempra's 2026 proxy statement outlines strong 2025 performance, a sharpened focus on regulated utility investments, and key shareholder voting matters including director elections and executive compensation.

Sempra amends its proxy statement to reflect Jennifer M. Kirk's upcoming role as CEO of Exubrion Therapeutics, a veterinary therapeutics company.

Sempra has filed a definitive proxy statement with the Securities and Exchange Commission.

Sempra's 2025 Annual Shareholders Meeting will be held virtually on May 13, 2025, with shareholders voting on director elections, auditor ratification, and executive compensation.

Sempra's recent proxy statement emphasizes its strong financial performance, diverse board, and recommendations against shareholder proposals regarding severance and environmental reporting.

Sempra has filed a definitive proxy statement with the Securities and Exchange Commission.

Sempra's 2024 proxy statement invites shareholders to the annual meeting on May 9, 2024, highlighting the company's achievements, governance practices, and matters for shareholder voting.